Chul Kim, MD

Articles by Chul Kim, MD

Interpreting the TOP Study and Comparing FLAURA2 and MARIPOSA Data

BySandip Patel, MD,Chul Kim, MD

July 30th 2026

This segment interprets the TOP study findings and their practice implications.

TP53 Co-Mutation Background and the TOP Study Design and Results

BySandip Patel, MD,Chul Kim, MD

July 30th 2026

This opening segment introduces an OncLive program built around ASCO data on risk-guided treatment intensification and sequencing in EGFR-mutated advanced non-small cell lung cancer (NSCLC).

Chul Kim, MD

Articles by Chul Kim, MD

Interpreting the TOP Study and Comparing FLAURA2 and MARIPOSA Data

TP53 Co-Mutation Background and the TOP Study Design and Results

Latest Updated Articles

Trending on OncLive

FDA Advisory Committee to Weigh RP1 Plus Nivolumab in Anti–PD-1–Pretreated Advanced Melanoma

FDA Grants RMAT and Fast Track Designations to Cema-Cel for First-Line LBCL

Dr Hashmi on the Identification of Candidates for CAR T-Cell Therapy in Early R/R Myeloma

Dr Secord on Combining Mocertatug Rezetecan With Dostarlimab in Endometrial Cancer

Novel CAR T-Cell Therapy Offers Promising Option for Hard-to-Treat Kidney Cancer